Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:1068-1076, 2005
© 2005 by the American Diabetes Association, Inc.

Emerging Treatments and Technologies
Original Article

Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes

The Diabetes Prevention Trial–Type 1

The Diabetes Prevention Trial-Type 1 Study Group

Address correspondence and reprint requests to Jay S. Skyler, MD, DPT-1 Study Chairman, University of Miami, P.O. Box 016960 [D-110], Miami, FL 33101-6960. E-mail: jskyler{at}miami.edu

OBJECTIVE—This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes.

RESEARCH DESIGN AND METHODS—We screened 103,391 first- and second-degree relatives of patients with type 1 diabetes and analyzed 97,273 samples for islet cell antibodies. A total of 3,483 were antibody positive; 2,523 underwent genetic, immunological, and metabolic staging to quantify risk of developing diabetes; 388 had a 5-year risk projection of 26–50%; and 372 (median age 10.25 years) were randomly assigned to oral insulin (7.5 mg/day) or placebo. Oral glucose tolerance tests were performed every 6 months. The median follow-up was 4.3 years, and the primary end point was diagnosis of diabetes.

RESULTS—Diabetes was diagnosed in 44 oral insulin and 53 placebo subjects. Annualized rate of diabetes was similar in both groups: 6.4% with oral insulin and 8.2% with placebo (hazard ratio 0.764, P = 0.189). In a hypothesis-generating analysis of a subgroup with insulin autoantibody (IAA) levels confirmed (on two occasions) ≥80 nU/ml (n = 263), there was the suggestion of benefit: annualized diabetes rate 6.2% with oral insulin and 10.4% with placebo (0.566, P = 0.015).

CONCLUSIONS—It is possible to identify individuals at high risk for type 1 diabetes and to enroll them in a large, multisite, randomized, controlled clinical trial. However, oral insulin did not delay or prevent type 1 diabetes. Further studies are needed to explore the potential role of oral insulin in delaying diabetes in relatives similar to those in the subgroup with higher IAA levels.

Abbreviations: DPT-1, Diabetes Prevention Trial–Type 1 • FPG, fasting plasma glucose • FPIR, first-phase insulin response • IAA, insulin autoantibody • ICA, islet cell antibody • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • OGT, oral glucose tolerance


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Tsui, V. Naik, N. Hoa, C. J. Hwang, N. F. Afifiyan, A. Sinha Hikim, A. G. Gianoukakis, R. S. Douglas, and T. J. Smith
Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves' Disease
J. Immunol., September 15, 2008; 181(6): 4397 - 4405.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. Butty, C. Campbell, D. Mathis, C. Benoist, and the DPT-1 Study Group
Impact of Diabetes Susceptibility Loci on Progression From Pre-Diabetes to Diabetes in At-Risk Individuals of the Diabetes Prevention Trial-Type 1 (DPT-1)
Diabetes, September 1, 2008; 57(9): 2348 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Maruyama, S. Tanaka, A. Shimada, O. Funae, A. Kasuga, A. Kanatsuka, I. Takei, S. Yamada, N. Harii, H. Shimura, et al.
Insulin Intervention in Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2115 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Krishnamurthy, L. Mariana, S. A. Gellert, P. G. Colman, L. C. Harrison, A. M. Lew, P. Santamaria, H. E. Thomas, and T. W. H. Kay
Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice
J. Immunol., April 1, 2008; 180(7): 4458 - 4464.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Sosenko, J. P. Krischer, J. P. Palmer, J. Mahon, C. Cowie, C. J. Greenbaum, D. Cuthbertson, J. M. Lachin, J. S. Skyler, and the Diabetes Prevention Trial-Type 1 Study Group
A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial-Type 1
Diabetes Care, March 1, 2008; 31(3): 528 - 533.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. A. Hinke
Finding GAD: Early Detection of {beta}-Cell Injury
Endocrinology, October 1, 2007; 148(10): 4568 - 4571.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner
Immunological Responses to Exogenous Insulin
Endocr. Rev., October 1, 2007; 28(6): 625 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Xu, D. Cuthbertson, C. Greenbaum, J. P. Palmer, J. P. Krischer, and for the Diabetes Prevention Trial Type 1 Study Gro
Role of Insulin Resistance in Predicting Progression to Type 1 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2314 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. S. Skyler
Cellular Therapy for Type 1 Diabetes: Has the Time Come?
JAMA, April 11, 2007; 297(14): 1599 - 1600.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al.
Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1
Diabetes Care, January 1, 2007; 30(1): 38 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Hanninen, R. Nurmela, M. Maksimow, J. Heino, S. Jalkanen, and C. Kurts
Islet {beta}-Cell-Specific T Cells Can Use Different Homing Mechanisms to Infiltrate and Destroy Pancreatic Islets
Am. J. Pathol., January 1, 2007; 170(1): 240 - 250.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. M. Gillespie
Type 1 diabetes: pathogenesis and prevention.
Can. Med. Assoc. J., July 18, 2006; 175(2): 165 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
D. A Lawlor and N. Chaturvedi
Treatment and prevention of obesity--are there critical periods for intervention?
Int. J. Epidemiol., February 1, 2006; 35(1): 3 - 9.
[Full Text] [PDF]

Home page
 DiabetesHome page
G. Stenstrom, A. Gottsater, E. Bakhtadze, B. Berger, and G. Sundkvist
Latent Autoimmune Diabetes in Adults: Definition, Prevalence, {beta}-Cell Function, and Treatment
Diabetes, December 1, 2005; 54(suppl_2): S68 - S72.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Endocrinology & Metabolism News, June 2005
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 16a - 16a.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.